Cargando…
Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101907/ https://www.ncbi.nlm.nih.gov/pubmed/33956908 http://dx.doi.org/10.1371/journal.pone.0251671 |
Ejemplares similares
-
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer
por: Frame, Sheelagh, et al.
Publicado: (2020) -
Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
por: Chantkran, Wittawat, et al.
Publicado: (2021) -
Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
por: Chantkran, Wittawat, et al.
Publicado: (2021) -
Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells
por: Chen, Rong, et al.
Publicado: (2022) -
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM
por: Juric, Viktorija, et al.
Publicado: (2021)